Published in final edited form as:

Mol Neurobiol. 2012 February ; 45(1): 30–42. doi:10.1007/s12035-011-8217-x.

Inhibitory Synaptic Regulation of Motoneurons: A New Target of Disease Mechanisms in Amyotrophic Lateral Sclerosis

Lee J. Martin^{1,2,3} and Qing Chang¹

¹Department of Pathology, Division of Neuropathology, Johns Hopkins University School of Medicine, 558 Ross Building, 720 Rutland Avenue, Baltimore, MD 21205-2196, USA

²Pathobiology Graduate Program, Johns Hopkins University School of Medicine, Baltimore, MD 21205-2196, USA

³Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205-2196, USA

Abstract

Amyotrophic lateral sclerosis (ALS) is the third most common adult-onset neurodegenerative disease. It causes the degeneration of motoneurons and is fatal due to paralysis, particularly of respiratory muscles. ALS can be inherited, and specific disease-causing genes have been identified, but the mechanisms causing motoneuron death in ALS are not understood. No effective treatments exist for ALS. One well-studied theory of ALS pathogenesis involves faulty RNA editing and abnormal activation of specific glutamate receptors as well as failure of glutamate transport resulting in glutamate excitotoxicity; however, the excitotoxicity theory is challenged by the inability of anti-glutamate drugs to have major disease-modifying effects clinically. Nevertheless, hyperexcitability of upper and lower motoneurons is a feature of human ALS and transgenic (tg) mouse models of ALS. Motoneuron excitability is strongly modulated by synaptic inhibition mediated by presynaptic glycinergic and GABAergic innervations and postsynaptic glycine receptors (GlyR) and GABA_A receptors; yet, the integrity of inhibitory systems regulating motoneurons has been understudied in experimental models, despite findings in human ALS suggesting that they may be affected. We have found in tg mice expressing a mutant form of human superoxide dismutase-1 (hSOD1) with a Gly93 → Ala substitution (G93A-hSOD1), causing familial ALS, that subsets of spinal interneurons degenerate. Inhibitory glycinergic innervation of spinal motoneurons becomes deficient before motoneuron degeneration is evident in G93A-hSOD1 mice. Motoneurons in these ALS mice also have insufficient synaptic inhibition as reflected by smaller GlyR currents, smaller GlyR clusters on their plasma membrane, and lower expression of GlyR1α mRNA compared to wild-type motoneurons. In contrast, GABAergic innervation of ALS mouse motoneurons and GABA_A receptor function appear normal. Abnormal synaptic inhibition resulting from dysfunction of interneurons and motoneuron GlyRs is a new direction for unveiling mechanisms of ALS pathogenesis that could be relevant to new therapies for ALS.

Keywords

Chloride channel; Glutamate receptor; Glycine receptor; Hb9-eGFP; Excitotoxicity; Hyperexcitability; Interneuron; Renshaw cell

Introduction

Amyotrophic lateral sclerosis (ALS) is a progressive and severely disabling fatal adult-onset neurological disease characterized by initial muscle spasticity, cramps, and fasciculations, and then muscle weakness, atrophy, and eventual paralysis and death typically 3 to 5 years after symptoms begin [1, 2]. More than 5,000 people in the USA are diagnosed with ALS each year (ALS Association, <http://www.alsa.org>), and the global incidence of ALS is about two per 100,000 persons [3]. The cause of the spasticity, paralysis, and death is believed to be progressive degeneration and elimination of upper motoneurons in cerebral cortex and lower motoneurons in brainstem and spinal cord [1, 4, 5]. Other than life support management, no effective treatments exist for ALS [2, 3, 6]. The molecular pathogenesis of ALS is understood poorly [5, 7, 8], contributing to the lack of appropriate target identification and effective mechanism-based therapies to treat this disease. The majority of ALS cases are sporadic with few known genetic contributions [1, 5, 7].

Familial forms of ALS are autosomal dominant or recessive and make up ~5% of all ALS cases [7]. ALS-linked mutations occur in the genes encoding Cu/Zn superoxide dismutase-1 (SOD1, *ALS1*), Alsin (*ALS2*), senataxin (*ALS4*), fused in sarcoma (FUS, *ALS6*), vesicle associated membrane protein (VAMP/synaptobrevin)-associated protein B (VAPB, *ALS8*), p150 dynactin (DCTN1), TAR-DNA binding protein (TADBP or TDP43, *ALS10*), and optineurin (*ALS12*) [7, 9–12]. Variations in the phosphoinositide phosphatase *FIG4* gene cause *ALS11* [13]. Several other genes are believed to be susceptibility factors for ALS.

Mouse Models of SOD1-Linked ALS

Autosomal dominant mutations in the *SOD1* gene occur in ~20% of familial ALS cases [9, 14]. SOD1 is a metalloenzyme comprising 153 amino acids (~16 kDa) that binds one copper ion and one zinc ion per subunit and is active as a non-covalently linked homodimer [15]. SOD1 is responsible, through catalytic dismutation, for the detoxification and maintenance of intracellular $O_2^{\bullet-}$ concentration in the low femtomolar range [15]. SOD1 is ubiquitous (intracellular SOD concentrations are typically ~10–40 μ M) in most tissues, possibly with highest levels in neurons [16]. Mutated human SOD1 (hSOD1) proteins appear to acquire a toxic property or function, rather than having diminished $O_2^{\bullet-}$ scavenging activity [14, 17, 18]. Wild-type SOD1 can gain toxic properties through loss of Zn [19] and oxidative modification [20, 21]. G93A-hSOD1 has enhanced free radical-generating capacity compared to wild-type enzyme [18] and can catalyze protein oxidation by hydroxyl-like intermediates and carbonate radical [22]. Toxic properties of mutant hSOD1 might also be mediated through protein binding or aggregation [23].

Transgenic (tg) mice expressing different mutated *hSOD1* genes (G93A, G37R, G85R) develop fatal motoneuron disease resembling ALS in humans [24]. In the original lines of mice, hSOD1 is expressed ubiquitously, driven by its endogenous promoter in a tissue/cell non-selective pattern, on a background of normal wild-type mouse SOD1 [24]. Effects of this human mutant gene in mice are profound. Hemizygous tg mice expressing a high copy number of the G93A-hSOD1 mutant become completely paralyzed and die at ~16–18 weeks of age [24]. hSOD1 mice with reduced transgene copy number have a much slower disease progression and die at ~7–9 months of age [24, 25].

The extent to which specific intrinsic abnormalities within motoneurons and other cells in spinal cord contribute to the pathogenesis in models of ALS is discrepant. In tg mice expressing mutant hSOD1 selectively in neurons driven by a *Thy1* promoter, motoneuron degeneration was absent [26, 27]; however, other studies have shown that neuron-specific expression of mutant hSOD1 is sufficient to induce motoneuron degeneration in mice [28, 29]. Tg mice with astrocyte-specific expression of mutant hSOD1 did not develop disease

[30], but cell culture studies reveal that mutant hSOD1-expressing astrocytes can cause degenerative changes in wild-type motoneurons and worsen toxicity of mutant hSOD1 in motoneurons [31]. Mutant hSOD1 expressed in microglia might also be toxic to motoneurons in mice [32, 33] and in cell culture [34]. Furthermore, degeneration of mutant hSOD1-expressing motoneurons that are surrounded by wild-type astrocytes or microglia appears delayed or prevented in chimeric mice [35], and transplantation of wild-type neural progenitor cells in spinal cord of mutant hSOD1 tg mice delays disease and extends survival, possibly by differentiating into glial cells [36]. However, elimination of proliferating microglia-expressing mutant hSOD1 in mice did not affect motoneuron degeneration [37]. More recently, a new tg mouse expressing mutant and wild-type hSOD1 only in skeletal muscle has been shown to develop motoneuron disease phenotype with cytopathological and biochemical changes very similar to those seen in human ALS motoneurons, demonstrating clearly a motoneuron-non-autonomous process for the degeneration of motoneurons in SOD1-linked ALS [38].

Disease Mechanisms in ALS

Many theories implicate perturbations in glutamatergic neurotransmission, axonal transport, proteasome and protein integrity, mitochondria, oxidative stress, copper chemistry, apoptosis, and inflammation in the mechanisms of ALS pathogenesis [4, 5, 39–42]. Some theories have been springboards for drug trials, but all therapeutic trials, except two with Riluzole, have failed.

Glutamate Excitotoxicity

One leading theory of ALS involves glutamate excitotoxicity [4, 42]. Reductions in the activity of glutamate transport occur in human sporadic ALS spinal cord [43] due to loss of astroglial glutamate transporter [44]. This abnormality could theoretically increase the extracellular concentrations of glutamate at synapses on motoneurons, leading to glutamate receptor-mediated excitotoxicity [4, 45]. However, reduced glutamate transport occurs in several other neurodegenerative settings, including cerebral hypoxia–ischemia, Alzheimer's disease, and Parkinson's disease [46, 47], and sometimes in the absence of neurodegeneration [48] and thus is not specific to ALS etiology.

Interestingly, disease-specific changes in RNA editing of the α -amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) glutamate receptor subunit 2 (GluR2) have been found in spinal motoneurons in human sporadic ALS autopsy cases [49]. These data show that, in normal motoneurons, the genomic DNA codon for glutamine (CAG) transcribed in the GluR2 pre-mRNA is converted post-translationally by an RNA-acting adenosine deaminase (ADAR) to an arginine-encoding codon (CGG) and that this RNA editing is faulty in sporadic ALS [49]. Subunits derived from unedited GluR2-mRNA translated with a glutamine at the Q/R site are Ca^{2+} -permeable [50–52]. In postmortem human ALS spinal motoneurons, analyzed at a single-cell level acquired by laser capture microdissection, AMPA receptors have reduced GluR2 subunit editing by ADAR, but RNA editing is normal in cerebellar Purkinje cells [49] and in another motor neuron disease called spinal bulbar muscular atrophy [53]. Genetically engineered mice without ADAR develop pathological changes suggestive of motoneuron degeneration [54]. Moreover, tg mice expressing a mutated *GluR2* gene that encodes asparagine at the Q/R site, causing GluR2 to be unedited, develop late-onset motoneuron disease [55]. In contrast, G93A-hSOD1 mice with enforced expression of normal editable GluR2 have delayed disease onset and decreased mortality [56]. G93A-hSOD1 mice that lack GluR2 entirely develop worse disease [57].

Hyperexcitability

Intrinsic motoneuron hyperexcitability can also be a contributor to excitotoxic vulnerability. The excitability of a neuron is reflected by the cell's ability to generate action potentials per unit of input [58]. Hyperexcitability of upper and lower motoneurons is a characteristic feature of human ALS and tg mouse models of ALS. Electrophysiological studies of live ALS patients reveal signs of hyperexcitability in motor cortex and surrounding areas [127]; however, such clinical studies lack cellular resolution and it is difficult to determine if the changes are intrinsic to specific cell populations. In tg mice, cultured embryonic spinal cord neurons expressing mutated hSOD1 have AMPA receptor channels with modified permeability, altered agonist cooperativity between the sites involved in the process of channel opening, and slower spontaneous synaptic events [59]. Intrinsic hyperexcitability of motoneurons is observed in neonatal (P7) spinal cord organotypic slices [60], neonatal (P4–P10) acute brainstem slices [61], dissociated embryonic spinal cord cell cultures [60, 62], and in embryonic cortical neuron cultures and acute slices of P29–P31 cerebral cortex [63] from high expressing G93A-hSOD1 mice. In these experiments, the passive membrane properties of motoneurons were unaltered, but the relationship between current injected and frequency of motoneuron firing was altered in mutant hSOD1-expressing cells, suggesting a change in membrane excitability. Motoneuron excitability abnormalities have also been reported in neonatal (P6–P10) acute spinal cord slices of G85R-hSOD1 mice and G93A-hSOD1 low-expressing mice [64]. In acute spinal cord slices from G85R-hSOD1 mice, lumbar motoneurons show reduced input resistance and altered frequency-intensity relationships in the second week of life, and these changes have been interpreted as structural changes indicative of larger motoneurons in mutant mice [65]. The signs of motoneuron hyperexcitability are thus occurring very early in disease progression. Even though the hyperexcitability abnormalities appear intrinsic to the motoneurons in ALS mice, it is currently not known if the changes are pathological or adaptive and if they are caused by direct actions of the mutant hSOD1 protein in motoneurons or indirectly by actions of the mutant protein in other cells such as skeletal myofibers, interneurons, or glial cells. Enhanced excitability of motoneurons in ALS mice does not appear to be due to increased monosynaptic input from group I muscle afferents, but might be related to increased excitability and bursting of spinal excitatory interneurons [66].

Abnormal motoneuron excitability in ALS could be due to involvement of Na⁺ channels [60, 67, 68]. Tetrodotoxin can protect against excitotoxicity in cultured primary embryonic motoneurons from G93A-hSOD1 mice [68]. Voltage-dependent Na⁺ channels in cultured primary embryonic motoneurons from G93A-hSOD1 mice also show enhanced recovery from fast inactivation, but voltage dependency of activation and steady-state inactivation appear normal [67]. A contributor to neuronal hyperexcitability is the persistent inward current generated by Na⁺ channels [69]. Persistent Na⁺ currents have been shown to be increased in spinal cord and cerebral cortex neurons in mutant hSOD1 tg mice in several different preparations, including dissociated embryonic spinal cord culture and neonatal spinal cord slices [60, 61, 64, 69] and dissociated embryonic cortical neuron culture [70]. The finding of increased persistent Na⁺ current in cultured cortical neurons from mutant hSOD1 tg mice [70] is interesting because these mice generally do not develop overt cortical pathology [71], but subtle dendritic abnormalities have been found on prefrontal cortex pyramidal neurons [72] which could be evidence for aberrant neuroplasticity.

Motoneurons in ALS have Deficient Inhibition

The glutamate excitotoxicity and hyperexcitability theories of ALS emphasize the contribution of excessive synaptic excitation in part through AMPA receptors [4, 42, 73] and Na⁺ channels [60, 67–69], while the possibility of insufficient synaptic inhibition has been theorized based on clinical data [127] but largely ignored experimentally. Abnormal GABA

and glycine levels are observed in ALS patients [74, 75]. In human ALS autopsy spinal cord, glycine binding sites are reduced in anterior horn [76, 77], and in human ALS autopsy motor cortex, some GABA_A receptor subunits show reduced levels of mRNA expression [78]. Adult tg G93A-hSOD1 mouse spinal cord [79] and organotypic spinal cord-slice cultures from embryonic G93A-hSOD1 tg mice [80] show evidence for imbalanced excitatory and inhibitory innervations, possibly indicative of aberrant or failed neuroplasticity. Based on these findings, aberrant inhibition could also have a role in ALS mechanisms of disease.

Spinal cord motoneurons receive extensive glycinergic and GABAergic innervations from vast numbers of spinal interneurons [81–83], and they express glycine receptor (GlyR) and GABA_A receptor chloride-conducting ion channels which regulate motoneuron excitability through various mechanisms (Fig. 1) [84]. GlyRs isolated from mammalian spinal cord are pentameric membrane proteins composed of α and β subunits (Table 1) [85]. GlyRs exhibit subtype heterogeneity due to four isoforms of α subunit ($\alpha 1$ – $\alpha 4$) [86, 87]. GlyRs in immature neurons contain the abundantly expressed $\alpha 2$ subunit, while GlyRs in mature neurons contain predominantly the $\alpha 1$ subunit within 2 weeks after birth [88]. The $\alpha 3$ subunit is mainly expressed in the cerebellum [88] and the $\alpha 4$ subunit is a murine gene that is not expressed in humans [89]. The majority of glycinergic neurotransmission in adults is mediated by $\alpha 1\beta$ GlyRs (Table 1). GABA_A receptors are also pentameric pore-forming membrane proteins and can be assembled from six different α subunits, three different β subunits, three different γ subunits, as well as δ , ϵ , π , and θ subunits (Table 2) [90]. α and β subunits are both required to generate a functional GABA-gated chloride ion channel with the most common composition being $\alpha 1\beta 2\gamma 2$, but this varies depending on CNS regions and cell type (Table 2) [90]. In adult rat brain, facial, hypoglossal, and trigeminal motoneurons differ from oculomotor, trochlear, and abducens motoneurons in their expression of GABA_A receptor subunits, GlyR/GABA_A receptor density ratios, and presence of synaptic versus extrasynaptic GABA_A receptors [91]. These findings might be important because, in human ALS, brainstem and spinal motoneurons are differentially affected; motoneurons in anterior horn and the facial, hypoglossal, and trigeminal cranial nerve nuclei are more vulnerable than motoneurons in Onuf's nucleus and the oculomotor, trochlear, and abducens cranial nerve nuclei [92].

Primary Cell Culture as a Model for Studying Motoneuron Function in ALS

In vitro models, including primary cell culture and slice preparations, offer several advantages in studying the function of individual neurons as well as neuronal circuits. First, these isolated preparations represent simplified systems that allow study of neuronal properties and cellular mechanisms without confounding by uncontrolled “outside” modifiers of synaptic and channel function such as steroids, hormones, and plasma proteins. Second, the internal and external solution of the neuron can be controlled, thus providing opportunities for testing the influence of drugs or mimicking the physiological conditions, but this can also cause “run-down.” Finally, it is feasible to combine electrophysiological and powerful single-cell molecular or genetic techniques on these preparations, such as RT-PCR and genotyping, thus allowing for direct correlation between structure and function at the ion channel level. Compared to acute slice preparations, neurons maintained in dissociated primary cultures have better stability for patch-clamp recordings. Although dissociated embryonic spinal cord cultures have disrupted anatomic architecture, they can develop spontaneously synaptic connections mimicking the spinal cord architecture [93] and network synaptic activity, including bursts with oscillations as demonstrated with multi-electrode arrays [94]. Organotypic slice cultures of embryonic spinal cord have better maintained architecture [95]. Nevertheless, in dissociated embryonic spinal cord cultures, the neuronal surface is better exposed to allow more optimal access of solutions and

pharmacological agents to neurons, and, since the neurons are in a monolayer with modest cellular vestments, the intracellular contents can be harvested more cleanly for single-cell RT-PCR (Fig. 2) [93].

Although primary cell culture systems are well suited for studying neuronal junctions, the information on neuron physiology in models of ALS is sparse, in part, because of difficulties in unequivocally identifying motoneurons in culture. Previously, the identities of motoneurons in culture were confirmed using immunohistochemistry. Motoneurons in embryonic spinal cord cultures were fixed and identified using antibodies to non-phosphorylated neurofilament SMI-32 and the acetylcholine synthesizing enzyme choline acetyltransferase [96, 97]. We use tg mice that express enhanced green fluorescent protein (eGFP) driven by the Hb9 promoter [98–100] to identify motoneurons [83, 93]. Hb9-eGFP labeling reveals good morphological details (Fig. 2a), and, more importantly, it labels living motoneurons essential for electrophysiological studies. In these mice eGFP is also expressed in a small subset of spinal interneurons, but these cells are distinctly different morphologically from motoneurons in vivo and in culture [93, 101].

We developed using Hb9-eGFP tg mice a dissociated mixed total spinal cord culture that includes all neighboring cells in spinal cord capable of supporting the survival of cultured motoneurons. Motoneurons in our cultures stay healthy for at least 4 weeks without deterioration of morphology and physiological functions [93]. Our motoneuron cell culture approach is distinctly different from, motoneuron enrichment techniques, utilizing density gradients [102], retrograde labeling [103, 104], and immunopanning [105], which give low yield of motoneurons or lack complete specificity for motoneurons. In addition, removal of other spinal cord neurons and glial cells that interact with motoneurons can alter their survival or phenotypes [106]. In previous electrophysiology studies, putative motoneurons in mixed spinal cord culture were visually identified by their morphological appearance and threshold diameter criteria ($>28\text{ }\mu\text{m}$) [62, 107]. Because the amount of motoneurons relative to all other cells in the total spinal cord culture is very low ($<1\%$), and there are other cells that are large ($>28\text{ }\mu\text{m}$), this method does not reveal sufficient morphological detail and is not specific for motoneurons; thus, the number of motoneurons is prone to overestimation and the recordings could be from heterogeneous cells. Our culture model using genetic labeling of motoneurons solves these problems (Fig. 2) [93].

We used this motoneuron cell culture as a model to study physiological consequences of a genetic mutation causing ALS. Studies have shown that primary spinal cord neuron cultures express functional GlyRs forming postsynaptic receptor aggregates [108–110] and that adult GlyR α 1 subunit was detected within the second week of culture [111, 112]. Using immunocytochemistry and confocal microscopy, we have demonstrated robust localization of the GlyR α 1 on cultured motoneurons at times when recordings were made (Fig. 2b). Furthermore, we confirmed the postsynaptic localization of GlyRs and their associations with presynaptic glycinergic terminals by their colocalization with gephyrin (Fig. 2b), synaptophysin, and glycine transporter-2 (GlyT2) [93].

GlyRs are Abnormal in Spinal Motoneurons in ALS Mice

We are examining the consequences of ALS-causing mutant genes on neuron synaptic function because little is known about motoneuron functional changes in ALS and how mutant proteins cause functional abnormalities and disease. Using whole-cell patch clamp recordings, we have shown that glycine-evoked current density is significantly smaller in large-sized (diameter $>28\text{ }\mu\text{m}$) G93A-hSOD1 motoneurons compared with control. Furthermore, the averaged current densities of spontaneous glycinergic miniature inhibitory postsynaptic currents (mIPSCs) are significantly smaller in the large-sized G93A-hSOD1 motoneurons than in control motoneurons. In contrast, glycine-evoked currents and

glycinergic mIPSCs in a morphologically distinct subgroup of medium-sized (diameter 10–28 μm) Hb9-eGFP⁺ motoneurons, presumably gamma or slow-type alpha motoneurons, are not different from control [101]. These results indicate that GlyR inhibitory insufficiency in motoneuron pools is specific for large α -motoneurons [101].

GABA_A Receptor Currents are not Affected in G93A-hSOD1 Mouse Motoneurons

To determine if the functional abnormalities in synaptic inhibition of ALS mouse motoneurons were general or specific to GlyRs, we studied GABA_AR currents. We did not find significant changes in the current density and kinetics of GABA_ARS in G93A-hSOD1 motoneurons [93]. Thus, of the two major ligand-gated chloride ion channels in spinal cord, the functional alteration appears to be selective for GlyRs.

Single-Cell Analysis of Motoneuron Gene Expression Using Real-Time RT-PCR

Reduced glycine-evoked currents and glycinergic mIPSCs in G93A-hSOD1 motoneurons could be caused by decreased expression of GlyRs. We have analyzed motoneuron gene expression by single-cell quantitative reverse transcription-PCR (qRT-PCR) following patch-clamp recordings on Hb9-eGFP⁺ motoneurons [93]. This methodology allows us to record specific properties of living neurons, to identify their ion channel functioning, and expression of their constituent channel subunits in the presence of human transgene expression. This approach offers a unique opportunity to study diseased motoneurons in direct relation to electrophysiology, molecular biology, and structure. Using single-cell qRT-PCR, we found decreased GlyR α 1 mRNA expression in G93A-hSOD1 motoneurons. By immunofluorescence (Fig. 2b), this finding was substantiated at the protein level by diminished expression of surface GlyRs on G93A-hSOD1 motoneurons [93].

Interneuron Networks in ALS

Interneuronal networks in spinal cord modulate motoneuron activity (Fig. 1). Spinal interneurons sculpt patterns of motoneuron activity critical for limb movements [82, 84, 113], but the involvement of interneurons in shaping motoneuron activity in non-locomotor activity, such as breathing, is defined less clearly [114–116]. Four classes of genetically distinct interneuron pools (V0–V3) are derived from the ventral embryonic spinal cord, with each class exhibiting unique features [82]. V0 interneurons are commissural. V1 interneurons are inhibitory with axons issuing rostroipsilaterally. V1 cells include the Renshaw cell and Ia inhibitory interneurons. V2 neurons project ipsilaterally and can be glutamatergic (V2a neurons) or inhibitory. V3 interneurons are excitatory commissural cells.

Glycinergic interneurons and synapses are abundant in adult mammalian spinal cord and brainstem [81, 83, 117, 118], regions vulnerable in ALS [92]. Renshaw cells, a type of glycinergic neuron, account for 2–3% of all ventral interneurons in mouse spinal cord [119]. They can be identified unambiguously by their size (mostly medium to large relative to other ventral interneurons), morphology, glycinergic (GlyT2⁺) and other markers (calbindin and nicotinic acetylcholine receptor α 2), large gephyrin clusters, location, and physiology (high postsynaptic sensitivity to acetylcholine and large glycine- and GABA-evoked currents) [120–122]. Renshaw cells receive extensive cholinergic, glutamatergic (mediated by AMPA receptors), GABAergic, and glycinergic inputs. They form synapses directly on α -motoneurons (Fig. 1), Ia inhibitory interneurons, and other Renshaw cells [122, 123]. The Renshaw cell to motoneuron ratio is estimated to be 1:5 [119]. Renshaw cells mediate recurrent inhibition of motoneurons (Fig. 1) (modulating recruitment and firing rate) and can modulate the inhibition produced by Ia inhibitory interneurons [119, 123, 124]. Renshaw cells exhibit vigorous, long-lasting EPSCs that evoke high-frequency burst discharges with initial instantaneous frequencies of $\sim$ 1,500 Hz [123, 125]. Thus, Renshaw cells require an

effective inhibitory synaptic input to modulate their excitatory responses [123]. Renshaw cell inhibitory synaptic properties develop during the first three postnatal weeks [126]. Ia inhibitory interneurons receive extensive convergent inputs from skeletal muscle Ia proprioceptive afferents (glutamatergic) and Renshaw cells.

Little is known about the roles that interneurons have in the disease mechanisms of human ALS and mouse models of ALS. Spasticity, as well as muscle cramps and fasciculations, are early clinical features of human ALS [127, 128] and are often treated by intrathecal baclofen (a GABA receptor agonist) [2, 3]. Clinical studies suggest that spinal cord recurrent inhibition is abnormally reduced and related to the spasticity [129]. Transcranial magnetic stimulation studies showing increased corticomotor hyperexcitability in ALS patients have been interpreted as being suggestive of cortical interneuron degeneration [130, 131]. However, because distal musculature has a relative lack of recurrent inhibition in humans and undergoes prominent early wasting in ALS, the involvement of Renshaw cells in the disease mechanisms has been questioned [132]. Nevertheless, loss of putative interneurons has been reported in human ALS primary motor cortex [133] and spinal cord [134–137]. In G93A-hSOD1 tg mice parvalbumin-containing cortical interneurons were found to be increased in motor and somatosensory cortex, possibly reflecting a compensatory adaptation [138]. In contrast, a loss of putative spinal interneurons has been reported in tg mice expressing mutated mouse SOD1 (instead of human mutant SOD1) [139].

Our first glimpse of spinal interneuron degeneration in ALS mice came from ubiquitin immunostaining, a marker for neural degeneration [140]. In G93A-hSOD1 mice at presymptomatic stages of the disease, ubiquitin⁺ neuritic abnormalities were found in the neuropil of the ventral horn, while motoneuron cell bodies did not display ubiquitin-containing inclusions. In early symptomatic mice, ubiquitin accumulated in smaller neurons with a fusiform or polygonal morphology but not yet in motoneuron cell bodies [140]. These ubiquitin-accumulating neurons were observed in the ventral horn and intermediate zone and were parvalbumin⁺, suggesting that they could be GABAergic or glycinergic spinal interneurons [126]. In G93A-hSOD1 mice, some spinal interneurons in laminae VII, VIII, and IX were reduced in number (Fig. 1), determined by counting cell bodies positive for calcium-binding proteins [140, 141]. This loss occurs long before the degeneration of motoneurons (Fig. 1), as assessed by mitochondrial swelling and cell body numbers [140, 141]. Motoneurons in these tg mice also lose glycinergic innervation, but not GABAergic or cholinergic innervation, at presymptomatic stages of disease [141]. A loss of inhibitory innervation of motoneurons as a feature of early disease in G93A-hSOD1 mice has been confirmed by electron microscopy [142]. The preservation of cholinergic C-boutons on motoneurons of G93A-hSOD1 mice has been confirmed by electron microscopy as well [143]. Some lost interneurons are parvalbumin⁺ [140] and others cells are calbindin⁺ [141]. The loss of parvalbumin in G93A-hSOD1 mouse spinal cord has also been shown by western blotting [144]. Some of the lost cells could be Renshaw cells because of their size, location, and calbindin calcium-binding protein signature [126, 145]. However, these interneurons could also be GABAergic, glutamatergic, or other glycinergic interneurons such as the Ia inhibitory interneurons [82, 126]. Renshaw cells have been implicated in the disease mechanisms in mouse and human ALS and have been identified as a target of neuroprotection mediated by lithium [146]. Another piece of evidence leading to our ALS-interneuron theory [140] was the finding that a subset of spinal cord-transplanted neuroprogenitors differentiates into interneurons in ALS mouse spinal cord, suggesting neuroplasticity response driven by a need for replacement or reconstitution of inhibitory circuits due to aberrant loss of interneurons [36]. Although motoneurons are a major target of spinal interneurons [119, 123, 124], we postulate that the loss of interneurons is a primary mechanism of disease and is not secondary to motoneuron loss because it precedes

motoneuron loss, and complete elimination of somatic motoneurons by target deprivation or neonatal axotomy does not affect interneuron number [147–149].

An early disease-initiating vulnerability of interneurons in ALS could be related to the intrinsic properties of interneurons compared to motoneurons, including high excitability with fast, repetitive, and prolonged action potential bursts, increased reliability of firing, high expression of Na⁺ channels, high expression of Ca²⁺-permeable AMPA receptors, spontaneous Ca²⁺ oscillations regulated by mitochondria, high oxidative metabolism, and substantial nitric oxide input [122, 150, 151]. This abnormality is likely to be incomplete because complete failure of glycinergic neurotransmission causes hyperekplexia [152], although ALS patients have some clinical features that can be interpreted as partially mimicking hyperekplexia, such as exaggerated reflexes (positive Babinski sign) and spasticity [1, 127]. Interestingly, a report on *spastic* mice which can present phenotypically with spasticity and then limb weakness and paralysis, caused by a mutant gene for GlyR β subunit, has shown early loss of ventral horn interneurons followed by motoneuron loss [153]. The participation of interneuron-related and GlyR-related early-onset pathology in ALS would be another example of motoneuron non-autonomous mechanisms of disease, but more importantly, it would identify new cellular (interneurons) and molecular (GlyRs) targets for disease therapy.

Opening New Therapeutic Doors to ALS Treatment

The only drug approved by the US Food and Drug Administration for the treatment of ALS is Riluzole, which blocks tetrodotoxin-sensitive Na⁺ channels and has anti-glutamate actions [2]. However, the efficacy of this drug in the treatment of ALS has been debated because its effects are marginal [2].

New clinically relevant molecular targets and drug developments and applications are necessary to move ALS therapy in new meaningful directions [2, 6]. Motoneurons in ALS mice have insufficient synaptic inhibition as reflected by reduced glycinergic innervation [141], smaller GlyR currents, smaller GlyR clusters on their plasma membrane, and lower expression of GlyR1 α mRNA compared to wild-type motoneurons [93]. These findings are important because glycinergic synaptic transmission is the main inhibitory neurotransmission system in spinal cord and modulates the excitability of motoneurons and interneurons [84, 87, 154]. It seems possible that inhibitory neural systems are disrupted as part of the pathogenesis in ALS (Fig. 1) and that this process might be engaged long before adulthood, thus the timing of disease could have much more protracted duration than generally appreciated. This work lays a foundation for the novel idea that motoneurons in ALS might undergo chronic stress due to inhibitory insufficiency. This inhibitory insufficiency could be a motoneuron autonomous process or secondary to glycinergic interneuron disease or dysfunction [141] and thus is a motoneuron non-autonomous process of degeneration involving Renshaw cells and neural networks (Fig. 1).

If our hypothesis is correct regarding glycinergic inhibitory insufficiency as a mechanism of disease, then potentially new avenues for therapeutics become available to ALS. Positive modulators of GlyRs and antagonists to glycine transporters (GlyT1 and GlyT2) are available for testing in preclinical models. Positive modulators of GlyRs are neurosteroids (progesterone and allopregnanolone), estrogen receptor modulators (tamoxifen), anesthetics (isoflurane, halothane, propofol, and nonanesthetic analogs of propofol), and cannabinoids [87, 155–158]. Tamoxifen, progesterone, and allopregnanolone are of particular interest because they increase spontaneous glycinergic mIPSCs in motoneurons [157, 159]. Extracellular concentrations of glycine at glycinergic synapses are regulated by Na⁺/Cl⁻-dependent GlyTs [118, 152, 154, 160]. GlyT1 is widely expressed in glial cells and

functions in lowering extracellular glycine concentration at the glycinergic synaptic cleft [154, 160]. GlyT2 is largely localized only to presynaptic terminals of glycinergic neurons found mostly in spinal cord and brainstem [117, 161]. Antagonists to both GlyT1 and GlyT2 are available that can increase extracellular concentrations of glycine in CNS in vivo [158]. This idea can open motoneuron disease to an entirely new, rational, mechanism-based treatment strategy utilizing GlyT and GlyR pharmacologies.

Acknowledgments

This work was supported by grants from the U.S. Public Health Service, National Institutes of Health, National Institute on Aging (R01-AG016282), and National Institute of Neurological Disorders and Stroke (R01-NS034100, R01-NS065895, and R01-NS052098).

References

1. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. *N Engl J Med*. 2001; 344:1688–1700. [PubMed: 11386269]
2. Zoccollella S, Santamato A, Lamberti P. Current and emerging treatments for amyotrophic lateral sclerosis. *Neuropsychiatr Dis Treat*. 2009; 5:577–595. [PubMed: 19966906]
3. Eisen A. Amyotrophic lateral sclerosis: a 40-year personal perspective. *J Clin Neurosci*. 2009; 16:505–512. [PubMed: 19231200]
4. Heath PR, Shaw PJ. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. *Muscle Nerve*. 2002; 26:438–458. [PubMed: 12362409]
5. Martin LJ. Mitochondrial and cell death mechanisms in neurodegenerative diseases. *Pharmaceuticals*. 2010; 3:839–915. [PubMed: 21258649]
6. Martin LJ. Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis. *IDrugs*. 2010; 13:1–13. [PubMed: 20024836]
7. Schymick JC, Talbot K, Traynor GJ. Genetics of amyotrophic lateral sclerosis. *Hum Mol Genet*. 2007; 16:R233–R242. [PubMed: 17911166]
8. Turner BJ, Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. *Prog Neurobiol*. 2008; 85:94–134. [PubMed: 18282652]
9. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. *Nature*. 1993; 362:59–62. [PubMed: 8446170]
10. Kabashi E, Valdmain PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, Bouchard J-P, Lacomblez L, Pochigaeva K, Salachas F, Pradat P-F, Camu W, Meininger V, Dupre N, Rouleau GA. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. *Nat Genet*. 2008; 40:572–574. [PubMed: 18372902]
11. Vance C, Rogej B, Hortobagyi T, de Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, Ganesalingam J, Williams KL, Tripathi V, Saraj S, Al-Chalabi A, Leigh N, Blair IP, Nicholson G, de Belleruche J, Gallo J-M, Miller CC, Shaw CE. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. *Science*. 2009; 323:1208–1211. [PubMed: 19251628]
12. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, Kinoshita Y, Kamada M, Nodera H, Suzuki H, Komure O, Matsuura S, Kobatake K, Morimoto N, Abe K, Suzuki N, Aoki M, Kawata A, Hirai T, Kato T, Ogasawara K, Hirano A, Takumi T, Kusaka H, Hagiwara K, Kaji R, Kawakami H. Mutations of optineurin in amyotrophic lateral sclerosis. *Nature*. 2010; 465:223–226. [PubMed: 20428114]
13. Chow CY, Lander JE, Bergren SK, Sapp PC, Grant AE, Jones JM, Everett L, Lenk GM, McKenna-Yasek DM, Weisman LS, Figlewicz D, Brown RH, Meisler MH. Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. *Am J Human Gen*. 2009; 84:85–88.
14. Deng H-X, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung W-Y, Getzoff ED, Hu P, Herzfeldt B, Roos RP, Warner C, Deng G, Soriano E, Smyth C, Parge HE, Ahmed A, Roses AD, Hallewell

- RA, Pericak-Vance MA, Siddique T. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. *Science*. 1993; 261:1047–1051. [PubMed: 8351519]
15. Fridovich I. Superoxide radical and superoxide dismutases. *Annu Rev Biochem*. 1995; 64:97–112. [PubMed: 7574505]
16. Rakhit R, Crow JP, Lepock JR, Kondejewski LH, Cashman NR, Chakrabartty A. Monomeric Cu, Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic sclerosis. *J Biol Chem*. 2004; 279:15499–15504. [PubMed: 14734542]
17. Borchelt DR, Lee MK, Slunt HH, Guarnieri M, Xu Z-S, Wong PC, Brown RH Jr, Price DL, Sisodia SS, Cleveland DW. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. *Proc Natl Acad Sci USA*. 1994; 91:8292–8296. [PubMed: 8058797]
18. Yim MB, Kang J-H, Yim H-S, Kwak H-S, Chock PB, Stadtman ER. A gain-of-function of an amyotrophic lateral sclerosis-associated Cu, Zn-superoxide dismutase mutant: an enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. *Proc Natl Acad Sci USA*. 1996; 93:5709–5714. [PubMed: 8650157]
19. Estévez AG, Crow JP, Sampson JB, Reiter C, Zhuang Y, Richardson GJ, Tarpey L, Barbeito MM, Beckman JS. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. *Science*. 1999; 286:2498–2500. [PubMed: 10617463]
20. Kabashi E, Valdmanis PN, Dion P, Rouleau GA. Oxidized/misfolded superoxide dismutase-1: the cause of all amyotrophic lateral sclerosis? *Ann Neurol*. 2007; 62:553–559. [PubMed: 18074357]
21. Ezzi SA, Urushitani M, Julien J-P. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. *J Neurochem*. 2007; 102:170–178. [PubMed: 17394546]
22. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. *Physiol Rev*. 2007; 87:315–424. [PubMed: 17237348]
23. Liochev SI, Fridovich I. Mutant Cu, Zn superoxide dismutases and familial amyotrophic lateral sclerosis: evaluation of oxidative hypotheses. *Free Radic Biol Med*. 2003; 34:1383–1389. [PubMed: 12757848]
24. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. *Science*. 1994; 264:1772–1775. [PubMed: 8209258]
25. Martin LJ, Gertz B, Pan Y, Price AC, Molkentin JD, Chang Q. The mitochondrial permeability transition pore in motor neurons: involvement in the pathobiology of ALS mice. *Exp Neurol*. 2009; 218:33–346. [PubMed: 19348801]
26. Pramatarova A, Laganière J, Ronssel J, Brisebois K, Rouleau GA. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. *J Neurosci*. 2001; 21:3369–3374. [PubMed: 11331366]
27. Lino MM, Schneider C, Caroni P. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. *J Neurosci*. 2002; 22:4825–4832. [PubMed: 12077179]
28. Jaarsma D, Teuling E, Haasdijk ED, Zeeuw CI, Hoogenraad CC. Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. *J Neurosci*. 2008; 28:2075–2088. [PubMed: 18305242]
29. Wang L, Sharma K, Deng H-X, Siddique T, Grisotti G, Liu E, Roos RP. Restricted expression of mutant SOD1 in spinal motor neurons and interneurons induces motor neuron pathology. *Neurobiol Dis*. 2008; 29:400–408. [PubMed: 18054242]
30. Gong YH, Parsadanian AS, Andreeva A, Snider WD, Elliott JL. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astocytosis but does not cause motoneuron degeneration. *J Neurosci*. 2000; 20:660–665. [PubMed: 10632595]
31. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, Przedborski S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. *Nat Neurosci*. 2007; 10:615–622. [PubMed: 17435755]

32. Boillée S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW. Onset and progression in inherited ALS determined by motor neurons and microglia. *Science*. 2006; 312:1389–1392. [PubMed: 16741123]
33. Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, Yen AA, Siklos L, McKercher SR, Appel SH. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. *Proc Natl Acad Sci USA*. 2006; 103:16021–16026. [PubMed: 17043238]
34. Xiao Q, Zhao W, Beers DR, Yen AA, Xie W, Henkel JS, Appel SH. Mutant SOD1^{G93A} microglia are more neurotoxic relative to wild-type microglia. *J Neurochem*. 2007; 102:2008–2019. [PubMed: 17555556]
35. Clement AM, Nguyen MD, Roberts EA, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. *Science*. 2003; 302:113–117. [PubMed: 14526083]
36. Martin LJ, Liu Z. Adult olfactory bulb neural precursor cell grafts provide temporary protection from motor neuron degeneration, improve motor function, and extend survival in amyotrophic lateral sclerosis mice. *J Neuropathol Exp Neurol*. 2007; 66:1002–1018. [PubMed: 17984682]
37. Gowing G, Philips T, Van Wijmeersch B, Audet J-N, Dewil M, van Den Bosch L, Billiau AD, Robberecht W, Julien J-P. Ablation of proliferating microglia does not affect motor neuron degeneration in amyotrophic lateral sclerosis caused by mutant superoxide dismutase. *J Neurosci*. 2008; 28:10234–10244. [PubMed: 18842883]
38. Wong M, Martin LJ. Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. *Hum Mol Genet*. 2010; 9:2284–2302. [PubMed: 20223753]
39. Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. *J Neuropathol Exp Neurol*. 1999; 58:459–471. [PubMed: 10331434]
40. Sathasivam S, Ince PG, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. *Neuropathol Appl Neurobiol*. 2001; 27:257–274. [PubMed: 11532157]
41. Trumbull KA, Beckman JS. A role for copper in the toxicity of zinc-deficient superoxide dismutase to motor neurons in amyotrophic lateral sclerosis. *Antioxid Redox Signal*. 2009; 11:1627–1639. [PubMed: 19309264]
42. Sasabe J, Aiso S. Aberrant control of motoneuronal excitability in amyotrophic lateral sclerosis: excitatory glutamate/D-serine vs. inhibitory glycine/ γ -aminobutanoic acid (GABA). *Chem Biodiv*. 2010; 7:1479–1490.
43. Rothstein JD, Martin LJ, Kuncel RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. *N Engl J Med*. 1992; 326:1464–1468. [PubMed: 1349424]
44. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncel RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. *Ann Neurol*. 1995; 38:73–84. [PubMed: 7611729]
45. Plaitakis A. Glutamate dysfunction and selective motor neuron degeneration in amyotrophic lateral sclerosis: a hypothesis. *Ann Neurol*. 1990; 28:3–8. [PubMed: 1973889]
46. Martin LJ, Brambrink AM, Lehmann C, Portera-Cailliau C, Koehler R, Rothstein J, Traystman RJ. Hypoxia-ischemia causes abnormalities in glutamate transporters and death of astroglia and neurons in newborn striatum. *Ann Neurol*. 1997; 42:335–348. [PubMed: 9307255]
47. Hinoi E, Takarada T, Tsuchihashi Y, Yoneda Y. Glutamate transporters as drug targets. *Curr Drug Targets*. 2005; 4:211–220.
48. Ginsberg SD, Rothstein JD, Price DL, Martin LJ. Fimbria–fornix transections selectively down-regulate subtypes of glutamate transporter and glutamate receptor proteins in septum and hippocampus. *J Neurochem*. 1996; 67:1208–1216. [PubMed: 8752128]
49. Kawahara Y, Ito K, Sun H, Aizawa H, Kanazawa I, Kwak S. Glutamate receptors: RNA editing and death of motor neurons. *Nature*. 2004; 427:801. [PubMed: 14985749]
50. Hollmann M, Hartley M, Heinemann S. Ca²⁺ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. *Science*. 1991; 252:851–853. [PubMed: 1709304]
51. Burnashev N, Monyer H, Seeburg P, Sakmann B. Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit. *Neuron*. 1992; 8:189–198. [PubMed: 1370372]

52. Lomeli H, Mosbacher J, Melcher T, et al. Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. *Science*. 1994; 266:1709–1713. [PubMed: 7992055]
53. Kawahara Y, Sun H, Ito K, Hideyama T, Aoki M, Sobue G, Tsuji S, Kwak S. Underediting of GluR2 mRNA, a neuronal death inducing molecular change in sporadic ALS, does not occur in motor neurons in ALS1 or SBMA. *Neurosci Res*. 2006; 545:11–14. [PubMed: 16225946]
54. Hideyama T, Yamashita T, Suzuki T, Tsuji S, Hignchi M, Seeburg PH, Takahashi R, Misawa H, Kwak S. Induced loss of ADAR2 engenders slow death of motor neurons from Q/R site-unedited GluR2. *J Neurosci*. 2010; 30:11917–11925. [PubMed: 20826656]
55. Kuner R, Groom AJ, Bresink I, et al. Late-onset motoneuron disease caused by a functionally modified AMPA receptor subunit. *Proc Natl Acad Sci USA*. 2005; 102:5826–5831. [PubMed: 15827116]
56. Tateno M, Sadakata H, Tanaka M, Itohar S, Shin R-M, Miura M, Masuda M, Aosaki T, Urushitani M, Misawa H, Takahashi R. Calcium-permeable AMPA receptors promote misfolding of mutant SOD1 protein and development of amyotrophic lateral sclerosis in a transgenic mouse model. *Hum Mol Genet*. 2004; 13:2183–2196. [PubMed: 15294873]
57. van Damme P, van den Bosch L, van Houtte CG, Robberecht W. GluR2-dependent properties of AMPA receptors determine the selective vulnerability of motor neurons to excitotoxicity. *J Neurophysiol*. 2002; 88:127–1287.
58. Neumann E, Nachmansohn D. Nerve excitability—towards an integrating concept. *Biomembranes*. 1975; 7:99–166. [PubMed: 1092381]
59. Pieri M, Albo F, Gaetti C, Spalloni A, Bengtson CP, Longone P, Cavalcanti S, Zona C. Altered excitability of motor neurons in a transgenic mouse model of familial amyotrophic lateral sclerosis. *Neurosci Lett*. 2003; 351:153–156. [PubMed: 14623129]
60. Kuo JJ, Schonewille M, Siddique T, Schults AN, Fu R, Bar PR, Anelli R, Heckman CJ, Kroese AB. Hyperexcitability of cultured spinal motoneurons from presymptomatic ALS mice. *J Neurophysiol*. 2004; 91:571–575. [PubMed: 14523070]
61. van Zundert B, Peuscher MH, Hynynen M, Chen A, Neve RL, Brown RH Jr, Constantine-Paton M, Bellingham MC. Neonatal neuronal circuitry shows hyperexcitable disturbance in a mouse model of the adult-onset neurodegenerative disease amyotrophic lateral sclerosis. *J Neurosci*. 2008; 28:10864–10874. [PubMed: 18945894]
62. Pieri M, Gaetti C, Spalloni A, Cavalcanti S, Mercuri N, Bernardi G, Longone P, Zona C. alpha-Ainino-3-hydroxy-5-methyl-isoxazole-4-propionate receptors in spinal cord motor neurons are altered in transgenic mice overexpressing human Cu, Zn superoxide dismutase (Gly93->Ala) mutation. *Neuroscience*. 2003; 122:47–58. [PubMed: 14596848]
63. Carunchio I, Curcio L, Pieri M, Pica F, Caioli S, Viscomi MT, Molinari M, Canu N, Bernardi G, Zona C. Increased levels of p70S6 phosphorylation in the G93A mouse model of amyotrophic lateral sclerosis and in valine-exposed cortical neurons in culture. *Exp Neurol*. 2010; 226:218–230. [PubMed: 20832409]
64. Pambo-Pambo A, Durand J, Gueritaud J-P. Early excitability changes in lumbar motoneurons of transgenic SOD1^{G85R} and SOD1^{G93A-Low} mice. *J Neurophysiol*. 2009; 102:3627–3642. [PubMed: 19828728]
65. Bories C, Amendola J, Lamotte d'Incamps B, Durand J. Early electrophysiological abnormalities in lumbar motoneurons in a transgenic mouse model of amyotrophic lateral sclerosis. *Eur J Neurosci*. 2007; 25:451–459. [PubMed: 17284186]
66. Jiang M, Schuster JE, Fu R, Siddique T, Heckman CJ. Progressive changes in synaptic inputs to motoneurons in adult sacral spinal cord of a mouse model of amyotrophic lateral sclerosis. *J Neurosci*. 2009; 29:15031–15038. [PubMed: 19955354]
67. Zona C, Pieri M, Carunchio I. Voltage-dependent sodium channels in spinal cord motor neurons display rapid recovery from fast inactivation in a mouse model of amyotrophic lateral sclerosis. *J Neurophysiol*. 2006; 96:3314–3322. [PubMed: 16899637]
68. Spalloni A, Pascucci T, Albo F, Ferrari F, Puglisi-Allegra S, Zona C, Barnardi G, Longone P. Altered vulnerability to kainite excitotoxicity of transgenic-Cu/Zn SOD1 neurons. *Neuroreport*. 2004; 15:2477–2480. [PubMed: 15538178]

69. Kuo JJ, Siddique T, Fu R, Heckman CJ. Increased persistent Na(+) current and its effect on excitability in motoneurons cultured from mutant SOD1 mice. *J Physiol.* 2005; 563:843–854. [PubMed: 15649979]
70. Pieri M, Carunchio I, Curcio L, Mercuri NB, Zona C. Increased persistent sodium current determines cortical hyperexcitability in a genetic model of familial amyotrophic lateral sclerosis. *Exp Neurol.* 2009; 215:368–379. [PubMed: 19071115]
71. Kata S. Amyotrophic lateral sclerosis models and human neuropathology: similarities and differences. *Acta Neuropathol.* 2008; 115:97–114. [PubMed: 18026741]
72. Sgobio C, Trbalza A, Spalloni A, Zona C, Carunchio I, Longone P, Ammassari-Teule M. Abnormal medial prefrontal cortex connectivity and defective fear extinction in the presymptomatic G93A SOD1 mouse model of ALS. *Genes Brain Behav.* 2008; 7:427–434. [PubMed: 18081837]
73. Kwak S, Hideyama T, Yamashita T, Aizawa. AMPA receptor-mediated neuromal death in sporadic ALS. *Neuropathology.* 2010; 30:182–188. [PubMed: 20102521]
74. Malessa S, Leigh PN, Bertel O, Sluga E, Hornykiewicz O. Amyotrophic lateral sclerosis: glutamate dehydrogenase and transmitter amino acids in the spinal cord. *J Neurol Neurosurg Psychiatry.* 1991; 54:984–988. [PubMed: 1686899]
75. Niebroj-Dobosz I, Janik P. Amino acids acting as transmitters in amyotrophic lateral sclerosis (ALS). *Acta Neurol Scand.* 1999; 100:6–11. [PubMed: 10416506]
76. Hayashi H, Suga M, Satake M, Tsubaki T. Reduced glycine receptor in the spinal cord in amyotrophic lateral sclerosis. *Ann Neurol.* 1981; 9:292–294. [PubMed: 6261674]
77. Whitehouse PJ, Wamsley JK, Zarbin MA, Price DL, Tourtellotte WW, Kuhar MJ. Amyotrophic lateral sclerosis: alterations in neurotransmitter receptors. *Ann Neurol.* 1983; 14:8–16. [PubMed: 6137185]
78. Petri S, Krampfl K, Hashemi F, Grothe C, Hori A, Dengler R, Buller J. Distribution of GABA_A receptor mRNA in the motor cortex of ALS patients. *J Neuropathol Exp Neurol.* 2003; 62:1041–1051. [PubMed: 14575239]
79. Schutz B. Imbalanced excitatory to inhibitory synaptic input precedes motor neuron degeneration in an animal model of amyotrophic lateral sclerosis. *Neurobiol Dis.* 2005; 20:131–140. [PubMed: 16137574]
80. Avossa D, Grandolfo M, Mazzarol F, Zatta M, Ballerini L. Early signs of motoneuron vulnerability in a disease model system: characterization of transverse slice cultures of spinal cord isolated from embryonic ALS mice. *Neuroscience.* 2006; 138:1179–1194. [PubMed: 16442737]
81. Zeilhofer HU, Studler B, Arabadzisz D, Schweizer C, Ahmadi S, Layh B, Bosl MR, Fritschy JM. Glycinergic neurons expressing enhanced green fluorescent protein in bacterial artificial chromosome transgenic mice. *J Comp Neurol.* 2005; 482:123–141. [PubMed: 15611994]
82. Goulding M. Circuits controlling vertebrate locomotion: moving in a new direction. *Nat Rev.* 2009; 10:507–518.
83. Martin LJ. An approach to experimental synaptic pathology using green fluorescent protein-transgenic mice and gene knockout mice to show mitochondrial permeability transition pore-driven excitotoxicity in interneurons and motoneurons. *Toxicol Pathol.* 2011; 39:220–233. [PubMed: 21378209]
84. Rekling JC, Funk GD, Bayliss DA, Dong XW, Feldman JL. Synaptic control of motoneuronal excitability. *Physiol Rev.* 2000; 80:767–852. [PubMed: 10747207]
85. Pfeiffer F, Graham D, Betz H. Purification by affinity chromatography of the glycine receptor of rat spinal cord. *J Biol Chem.* 1982; 257:9389–9393. [PubMed: 6286620]
86. Kuhse J, Betz H, Kirsch J. The inhibitory glycine receptor: architecture, synaptic localization and molecular pathology of a postsynaptic ion-channel complex. *Curr Opin Neurobiol.* 1995; 5:318–323. [PubMed: 7580154]
87. Lynch JW. Native glycine receptor subtypes and their physiological roles. *Neuropharmacology.* 2009; 56:303–309. [PubMed: 18721822]
88. Malosio ML, Marqueze-Pouey B, Kuhse J, Betz H. Widespread expression of glycine receptor subunit mRNAs in the adult and developing rat brain. *EMBO J.* 1991; 10:2401–2409. [PubMed: 1651228]

89. Matzenbach B, Maulet Y, Sefton L, Courtier B, Avner P, Guenet JL, Betz H. Structural analysis of mouse glycine receptor alpha subunit genes. Identification and chromosomal localization of a novel variant. *J Biol Chem.* 1994; 269:2607–2612. [PubMed: 7507926]
90. Olsen, RW.; Betz, H. GABA and glycine. In: Siegel, GJ.; Albers, RW.; Brady, ST.; Price, DL., editors. *Basic neurochemistry: molecular, cellular, and medical aspects.* 7th edn.. London: Elsevier; 2006. p. 291–301.
91. Lorenzo L-E, Barbe A, Portalier P, Fritschy J-M, Bras H. Differential expression of GABAA and glycine receptors in ALS-resistant vs ALS-vulnerable motoneurons: possible implications for selective vulnerability of motoneurons. *Eur J Neurosci.* 2006; 23:3161–3170. [PubMed: 16820006]
92. Hays, AO. The pathology of amyotrophic lateral sclerosis. In: Mitsumoto, H.; Przedborski, S.; Gordon, PH., editors. *Amyotrophic lateral sclerosis.* New York: Taylor & Francis; 2006. p. 43–80.
93. Chang Q, Martin LJ. Glycine receptor channels in spinal motoneurons are abnormal in a transgenic mouse model of amyotrophic lateral sclerosis. *J Neurosci.* 2011; 31:2815–2827. [PubMed: 21414903]
94. Yvon C, Czarnecki A, Streit J. Riluzole-induced oscillations in spinal networks. *J Neurophysiol.* 2007; 97:3607–3620. [PubMed: 17344372]
95. Avossa D, Rosato-Siri MD, Mazzarol F, Ballerini L. Spinal circuits formation: a study of developmentally regulated markers in organotypic cultures of embryonic mouse spinal cord. *Neuroscience.* 2003; 122:391–405. [PubMed: 14614905]
96. Carriedo SG, Yin HZ, Lamberta R, Weiss JH. In vitro kainate injury to large, SMI-32(+) spinal neurons is Ca²⁺ dependent. *Neuroreport.* 1995; 6:945–948. [PubMed: 7612889]
97. Richards LJ, Murphy M, Dutton R, Kilpatrick TJ, Puche AC, Key B, Tan SS, Talman PS, Bartlett PF. Lineage specification of neuronal precursors in the mouse spinal cord. *Proc Natl Acad Sci USA.* 1995; 92:10079–10083. [PubMed: 7479730]
98. Arber S, Han B, Mendelsohn M, Smith M, Jessell TM, Sockanathan S. Requirement for the homeobox gene Hb9 in the consolidation of motor neuron identity. *Neuron.* 1999; 23:659–674. [PubMed: 10482234]
99. Thaler J, Harrison K, Sharma K, Lettieri K, Kehrl J, Pfaff SL. Active suppression of interneuron programs within developing motor neurons revealed by analysis of homeodomain factor HB9. *Neuron.* 1999; 23:675–687. [PubMed: 10482235]
100. Wichterle H, Lieberam I, Porter JA, Jessell TM. Directed differentiation of embryonic stem cells into motor neurons. *Cell.* 2002; 110:385–397. [PubMed: 12176325]
101. Chang Q, Martin LJ. Motoneuron subtypes show specificity in glycine receptor channel abnormalities in a transgenic mouse model of amyotrophic lateral sclerosis. *Channels.* 2011; 5:1–5. [PubMed: 21263232]
102. Schnaar RI, Schaffner AE. Separation of cell types from embryonic chicken and rat spinal cord: characterization of motoneuron-enriched fractions. *J Neurosci.* 1981; 1:204–217. [PubMed: 7264717]
103. Calof AL, Reichardt LF. Motoneurons purified by cell sorting respond to two distinct activities in myotube-conditioned medium. *Dev Biol.* 1984; 106:194–210. [PubMed: 6489607]
104. Schaffner AE, St John PA, Barker JL. Fluorescence-activated cell sorting of embryonic mouse and rat motoneurons and their long-term survival in vitro. *J Neurosci.* 1987; 7:3088–3104. [PubMed: 2822863]
105. Camu W, Henderson CE. Purification of embryonic rat motoneurons by panning on a monoclonal antibody to the low-affinity NGF receptor. *J Neurosci Methods.* 1992; 44:59–70. [PubMed: 1434751]
106. O'Brien RJ, Fischbach GD. Isolation of embryonic chick motoneurons and their survival in vitro. *J Neurosci.* 1986; 6:3265–3274. [PubMed: 3772431]
107. Carunchio I, Mollinari C, Pieri M, Merlo D, Zona C. GAB(A) receptors present higher affinity and modified subunit composition in spinal motor neurons from a genetic model of amyotrophic lateral sclerosis. *Eur J Neurosci.* 2008; 28:1275–1285. [PubMed: 18973555]
108. Jackson MB, Lecar H, Brenneman DE, Fitzgerald S, Nelson PG. Electrical development in spinal cord cell culture. *J Neurosci.* 1982; 2:1052–1061. [PubMed: 7050310]

109. Hamill OP, Bormann J, Sakmann B. Activation of multiple-conductance state chloride channels in spinal neurones by glycine and GABA. *Nature*. 1983; 305:805–808. [PubMed: 6314144]
110. Nicola MA, Becker CM, Triller A. Development of glycine receptor alpha subunit in cultivated rat spinal neurons: an immunocytochemical study. *Neurosci Lett*. 1992; 138:173–178. [PubMed: 1328956]
111. Hoch W, Betz H, Schramm M, Wolters I, Becker CM. Modulation by NMDA receptor antagonists of glycine receptor isoform expression in cultured spinal cord neurons. *Eur J Neurosci*. 1992; 4:389–395. [PubMed: 12106346]
112. St John PA, Stephens SL. Adult-type glycine receptors form clusters on embryonic rat spinal cord neurons developing in vitro. *J Neurosci*. 1993; 13:2749–2757. [PubMed: 7687278]
113. Allain A-E, Le Corrionc H, Delpy A, Cazenave W, Meyrand P, Legendre P, Branchereau P. Maturation of the GABAergic transmission in normal and pathological motoneurons. *Neural Plast*. 2011;905624. [PubMed: 21785735]
114. Lee K-Z, Fuller DD. Neural control of phrenic motoneuron discharge. *Respir Physiol Neurobiol*. 2011; 179:71–79. [PubMed: 21376841]
115. Lane MA. Spinal respiratory motoneurons and interneurons. *Respir Physiol Neurobiol*. 2011; 179:3–13. [PubMed: 21782981]
116. Saywell SA, Ford TW, Meehan CF, Todd AJ, Kirkwood PA. Electrophysiological and morphological characterization of propriospinal interneurons in the thoracic spinal cord. *J Neurophysiol*. 2011; 105:806–826. [PubMed: 21106900]
117. Jursky F, Nelson N. Localization of glycine neurotransmitter transporter (GLYT2) reveals correlation with the distribution of glycine receptor. *J Neurochem*. 1995; 64:1026–1033. [PubMed: 7861131]
118. Luque JM, Nelson N, Richards JG. Cellular expression of glycine transporter 2 messenger RNA exclusively in rat hindbrain and spinal cord. *Neuroscience*. 1995; 64:525–535. [PubMed: 7700536]
119. Mentis GZ, Siembab VC, Zerda R, O'Donovan MJ, Alvarez FJ. Primary afferent synapses on developing and adult Renshaw cells. *J Neurosci*. 2006; 26:13297–13310. [PubMed: 17182780]
120. Willis WD, Willis JC. Location of Renshaw cells. *Nature*. 1964; 204:1213–1214. [PubMed: 14264393]
121. Curtis DR, Game CJ, Lodge D, McCulloch RM. A pharmacological study of Renshaw cell inhibition. *J Physiol*. 1976; 258:227–242. [PubMed: 940060]
122. Alvarez FJ, Fyffe RE. The continuing case for the Renshaw cell. *J Physiol*. 2007; 584(1):31–45. [PubMed: 17640932]
123. Eccles JC, Fatt P, Koketsu K. Cholinergic and inhibitory synapses in a pathway from motor-axon collaterals to motoneurons. *J Physiol*. 1954; 126:524–562. [PubMed: 13222354]
124. Renshaw B. Influence of discharge of motoneurons upon excitation of neighboring motoneurons. *J Neurophysiol*. 1941; 4:167–183.
125. Renshaw B. Central effects of centripetal impulses in axon of spinal ventral roots. *J Neurophysiol*. 1946; 9:191–204. [PubMed: 21028162]
126. Alvarez FJ, Jonas PC, Sapir T, Hartley R, Berrocal MC, Geiman EJ, Todd AJ, Goulding M. Postnatal phenotype and localization of spinal cord V1 derived interneurons. *J Comp Neurol*. 2005; 493:177–192. [PubMed: 16255029]
127. Eisen A, Weber M. Neurophysiological evaluation of cortical function in the early diagnosis of ALS. *Amyotroph Lateral Scler Other Motor Neuron Disord*. 2000; 1:S47–S51. [PubMed: 11464926]
128. Enterzari-Taher M, Eisen A, Stewart H, Nakajima M. Abnormalities of cortical inhibitory neurons in amyotrophic lateral sclerosis. *Muscle Nerve*. 1997; 20:65–71. [PubMed: 8995585]
129. Raynor EM, Shefner JM. Recurrent inhibition is decreased in patients with amyotrophic lateral sclerosis. *Neurology*. 1994; 44:2148–2153. [PubMed: 7969975]
130. Mills KR. The natural history of central motor abnormalities in amyotrophic lateral sclerosis. *Brain*. 2003; 126:2558–2566. [PubMed: 12937082]

131. Ziemann U, Winter M, Reimers CD, Reimers K, Tergau F, Paulus W. Impaired motor cortex inhibition in patients with amyotrophic lateral sclerosis: evidence from paired transcranial magnetic stimulation. *Neurology*. 1997; 49:1771–1772.
132. Mazzocchio R, Rossi A. Role of Renshaw cells in amyotrophic lateral sclerosis. *Muscle Nerve*. 2010; 41:441–443. [PubMed: 20082418]
133. Maekawa S, Al-Sarraj S, Kibble M, Landau S, Parnavelas J, Cotter D, Everall I, Leigh PN. Cortical selective vulnerability in motor neuron disease: a morphometric study. *Brain*. 2004; 127:1237–1251. [PubMed: 15130949]
134. Swash M, Leader M, Brown A, Swettenham KW. Focal loss of anterior horn cells in the cervical cord in motor neuron disease. *Brain*. 1986; 109:939–952. [PubMed: 3779374]
135. Oyanagi K, Ikuta F, Horikawa Y. Evidence for sequential degeneration of the neurons in the intermediate zone of spinal cord in amyotrophic lateral sclerosis: a topographic and quantitative investigation. *Acta Neuropathol*. 1989; 77:343–349. [PubMed: 2711828]
136. Stephens B, Guiloli RJ, Navarrete R, Newman P, Nikhar N, Lewis P. Widespread loss of neuronal populations in the spinal ventral horn in sporadic motor neuron disease. A morphometric study. *J Neurol Sci*. 2006; 244:41–58. [PubMed: 16487542]
137. Hayashi S, Amari M, Takatama M, Okamoto K. Morphometric and topographical studies of small neurons in sporadic amyotrophic lateral sclerosis gray matter. *Neuropathology*. 2007; 27:121–126. [PubMed: 17494512]
138. Minciacchi D, Kassa RM, Del Tongo C, Mariotti R, Bentivoglio M. Voronoi-based spatial analysis reveals selective interneuron changes in the cortex of FALS mice. *Exp Neurol*. 2009; 215:77–86. [PubMed: 18926824]
139. Morrison BM, Janssen WG, Gordon JW, Morrison JH. Time course of neuropathology in the spinal cord of G86R superoxide dismutase transgenic mice. *J Comp Neurol*. 1998; 391:64–77. [PubMed: 9527542]
140. Martin LJ, Liu Z, Chen K, Price AC, Pan Y, Swaby JA, Golden WC. Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase-1 transgenic mice: mechanisms of mitochondrial pathology and cell death. *J Comp Neurol*. 2007; 500:20–46. [PubMed: 17099894]
141. Chang Q, Martin LJ. Glycinergic innervation of motoneurons is deficient in amyotrophic lateral sclerosis mice: a quantitative confocal analysis. *Am J Pathol*. 2009; 174:574–585. [PubMed: 19116365]
142. Sunico CR, Dominguez G, Garcia-Verdugo JM, Osta R, Montero F, Moreno-Lopez B. Reduction in the motoneuron inhibitory/excitatory synaptic ratio in an early-symptomatic mouse model of amyotrophic lateral sclerosis. *Brain Pathol*. 2011; 21:1–15. [PubMed: 20653686]
143. Pullen AH, Athanasiou D. Increase in presynaptic territory of C-terminate on lumbar motoneurons of G93A SOD1 mice during disease progression. *Eur J Neurosci*. 2009; 29:551–561. [PubMed: 19187267]
144. Sasaki S, Warita LI, Komori T, Murakami T, Abe K, Iwata M. Parvalbumin and calbindin D-28k immunoreactivity in transgenic mice with a G93A mutant SOD1 gene. *Brain Res*. 2006; 1083:196–203. [PubMed: 16546142]
145. Carr PA, Alvarez FJ, Leman EA, Fyffe RE. Calbindin D28k expression in immunohistochemically identified Renshaw cells. *Neuroreport*. 1998; 9:2657–2661. [PubMed: 9721951]
146. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. *Proc Natl Acad Sci USA*. 2008; 105:2052–2057. [PubMed: 18250315]
147. Grieshammer U, Lewandoski M, Prevette D, Oppenheim RW, Martin GR. Muscle-specific cell ablation conditional upon Cre-mediated DNA recombination in transgenic mice leads to massive spinal and cranial motoneuron loss. *Dev Biol*. 1998; 197:234–247. [PubMed: 9630749]
148. Kablar B, Rudnicki MA. Development in the absence of skeletal muscle results in the sequential ablation of motor neurons from spinal cord to the brain. *Dev Biol*. 1999; 208:93–109. [PubMed: 10075844]
149. Lim SMC, Guiloff RJ, Navarrete R. Interneuronal survival and calbindin-D28K expression following motoneuron degeneration. *J Neural Sci*. 2000; 180:46–51.

150. Carr PA, Liu M, Zaruba RA. Enzyme histochemical profile of immunohistochemically identified Renshaw cells in rat lumbar spinal cord. *Brain Res Bull.* 2001; 54:669–674. [PubMed: 11403994]
151. Miles R. Diversity of inhibition. *Science.* 2000; 287:244–246. [PubMed: 10660424]
152. Gomez J, Ohno K, Hulsman S, Armsen W, Eulenburg V, Richter DW, Laube B, Betz H. Deletion of the mouse glycine transporter 2 results in a hyperekplexia phenotype and postnatal lethality. *Neuron.* 2003; 40:797–806. [PubMed: 14622583]
153. Molon A, Di Giovanni S, Hathout Y, Natale J, Hoffman EP. Functional recovery of glycine receptors in *spastic* murine model of startle disease. *Neurobiol Dis.* 2006; 21:291–304. [PubMed: 16182553]
154. Legendre P. The glycinergic inhibitory synapse. *Cell Mol Life Sci.* 2001; 58:760–793. [PubMed: 11437237]
155. O'Shea SM, Becker L, Weiher H, Betz H, Laube B. Propofol restores the function of “hyperekplexic” mutant glycine receptors *Xenopus* oocytes and mice. *J Neurosci.* 2004; 24:2322–2327. [PubMed: 14999083]
156. Xu T-X, Gong N, Xu T-L. Inhibitors of GlyT1 and GlyT2 differentially modulate inhibitory transmission. *Neuroreport.* 2005; 16:1227–1231. [PubMed: 16012354]
157. Chesnoy-Marchais D. The estrogen receptor modulator tamoxifen enhances spontaneous glycinergic synaptic inhibition of hypoglossal motoneurons. *Endocrinology.* 2005; 146:4302–4311. [PubMed: 15976053]
158. Nishikawa Y, Sasaki A, Kuraishi Y. Blockade of glycine transporter (GlyT2), but not GlyT1, ameliorates dynamic and static mechanical allodynia in mice with herpetic or postherpetic pain. *J Pharmacol Sci.* 2010; 112:352–360. [PubMed: 20173309]
159. Chesnoy-Marchais D. Progesterone and allopregnanolone enhance the miniature synaptic release of glycine in the rat hypoglossal nucleus. *Eur J Neurosci.* 2009; 30:2100–2111. [PubMed: 19930400]
160. Beato M. The time course of transmitter at glycinergic synapses onto motoneurons. *J Neurosci.* 2008; 28:7412–7425. [PubMed: 18632945]
161. Poyatos I, Ponce J, Aragon C, Gimenez C, Zafra F. The glycine transporter GLYT2 is a reliable marker for glycine-immunoreactive neurons. *Brain Res Mol Brain Res.* 1997; 49:63–70. [PubMed: 9387864]

Fig. 1. Schematic drawing of inhibitory insufficiency of motoneurons in ALS spinal cord. Shown is a very simplified network of cells in ventral horn comprised of motoneurons (cells with green nucleus and green axon) and interneurons (cells with red nucleus and red axon). The green axons are exiting the spinal cord from the ventral root exit zone. In the normal network, motoneurons issue axons with collaterals that contact glycinergic inhibitory interneurons (Renshaw cells) whose activation in turn silences the activity of motoneurons that express glycine receptor clusters (blue postsynaptic complex). In ALS transgenic mice, the spinal cord undergoes network failure early in disease resulting from degeneration and

loss of interneurons and abnormalities in motoneuron glycine receptor complex formation (*blue x*), possibly leading to hyperexcitability and excitotoxicity

\$watermark-text

\$watermark-text

\$watermark-text

Fig. 2. Identification and receptor characterization of motoneurons in Hb9-eGFP mouse spinal cord cultures. **a** Confocal microscopy showing a representative example of an Hb9-eGFP (*green*) expressing motoneuron in dissociated spinal cord cultures co-labeled with neurofilament SMI-32 antibody (*red*) and choline acetyltransferase (ChAT, *blue*). *Scale bar* = 20 μ m. **b** Confocal image showing the localization of glycine receptors (GlyR, *red*) in close apposition to postsynaptic scaffold protein gephyrin (Geph, *blue*) on the surface of the soma and proximal dendrites of an Hb9-eGFP (*green*) expressing motoneuron. *Scale bar* = 20 μ m

Table 1

Glycine receptor composition

Isoforms	Subunit size (kDa)	Endogenous assembly (adult)	Comment
$\alpha 1$, $\alpha 2$, $\alpha 3$, $\alpha 4$	48	$\alpha 1_3 \beta_2$, $\alpha 1_4 \beta_1$	$\alpha 4$ is murine, not found in human
β	58		Binds scaffold protein gephyrin

Table 2GABA_A receptor composition

Isoforms	Subunit size (kDa)	Endogenous assembly (adult)	Comment
$\alpha 1, \alpha 2, \alpha 3, \alpha 4, \alpha 5, \alpha 6$	52	$\alpha_1 \beta_2 \gamma_2$ (most common), but varies depending on CNS region and cell type	Must include both α and β subunits to form GABA-gated ion channel; $\alpha 1$ subunit binds gephyrin
$\beta 1, \beta 2, \beta 3$	54		Interacts with phosphoinositide-3 kinase
$\gamma 1, \gamma 2, \gamma 3$	53		Important for trafficking; has the benzodiazepine binding site
δ	51		Forms extrasynaptic receptors
ϵ	58		–
π	51		–
θ	72		–
$\rho 1, \rho 2, \rho 3$	56		Do not co-assemble with other subunits but homooligomerize in retina